13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting Hsp70 could help treat prostate cancer resistant to Xtandi enzalutamide and/or Zytiga abiraterone acetate. In human prostate cancer cell lines, high Hsp70 levels were associated...
17:16 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Orphazyme seeking path forward for arimoclomol in NPC after Phase II/III miss

Orphazyme A/S (CSE:ORPHA) said arimoclomol missed the primary endpoints in a Phase II/III trial to treat Niemann-Pick disease type C (NPC). The company plans to meet with FDA and EMA to determine next steps for...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro , cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:01 , Nov 16, 2017 |  BC Extra  |  Financial News

Protein misfolding play Orphazyme prices IPO

Protein misfolding company Orphazyme A/S (CSE:ORPHA TEMP) was unchanged on Thursday after it debuted on NASDAQ Copenhagen, raising DKK 600 million ($94.1 million) in an IPO through the sale of 7.5 million shares at DKK...
19:22 , Jul 28, 2017 |  BioCentury  |  Regulation

Ganging up in rare disease

A joint proposal from EMA and FDA that encourages companies to join multidrug platform trials for pediatric Gaucher’s disease came too late to serve its original purpose. But the proposal could provide a template for...
20:06 , Apr 28, 2017 |  BC Week In Review  |  Company News

Agenus restructuring news

In March, Agenus said it will reduce headcount by about 50. The company, which had 255 employees at Feb. 28, did not respond to inquiries. Agenus said it will focus on the development of its...
15:30 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

AutoSynVax: Ph I started

Agenus began an open-label, U.S. Phase I trial to evaluate 240 µg subcutaneous AutoSynVax plus the company's QS-21 Stimulon adjuvant given every 2 weeks for up to 1 year in about 20 patients. Agenus Inc....
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...